Table 2.

Features of the multi kinase inhibitors approved by the Food and Drug Administration (FDA) from 2011 to 2021. The order of drugs is tabulated in order of most recent to the oldest registration date.

No.	Generic Name of Drug	Brand Name and Company	First FDA/EMA Approved Date	Structure	Molecular Target	Route of Administration	Indication	Adverse Effects	Reference
1	Fedratinib	INREBIC Celgene Corporation, Summit, NJ, USA	FDA: 16 August 2019 EMA: 8 February 2021		JAK2 2	Oral	Myelofibrosis	Diarrhea, nausea, vomiting, constipation, anemia, thrombocytopenia	[66] 1, [67,68]
2	Gilteritinib	XOSPATA Astellas Pharma US, Inc., Northbrook, IL, USA	FDA: 28 November 2018 EMA: 24 October 2019		FLT3 3, AXL 4, ALK 5	Oral	Acute Myeloid Leukemia	Myalgia, arthralgia, increased levels of transaminases, fatigue, malaise, fever, diarrhea, dyspnea, edema, rash, pneumonia, sepsis, renal impairment	[69,70]
3	Midostaurin	RYDAPT Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA	FDA: 28 April 2017 EMA: 18 September 2017		c-Kit 6, PDGFRA 7, PDGFRB 8, FLT3 3, PKC 9, CDK1 10, SYK 11, VEGFR-2 12	Oral	Acute Myeloid Leukemia, Cutaneous Mastocytosis	Febrile neutropenia, nausea, vomiting, diarrhea, edema, mucositis, headache, device-related infection, abdominal pain, fatigue, pyrexia, dyspnea, musculoskeletal pain, constipation, epistaxis, upper respiratory tract infection, petechial, hyperglycemia,	[71,72]
4	Ponatinib	ICLUSIG Ariad Pharmaceuticals, Inc., Cambridge, MA, USA	FDA: 14 December 2012 EMA: 1 July 2013		BCR-ABL 13, VEGFRs 14, FGFRs 15, PDGFRs 16, RET 17, c-Kit 6, TIE2 18, FLT3 3	Oral	Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia	Hypertension, cardiac failure, abdominal pain, constipation, diarrhea, oral mucositis, febrile neutropenia, fatigue, pneumonia, headache, peripheral neuropathy, dizziness, pleural effusion, cough, dyspnea, rush, dry skin, arthralgia, myalgia, spasms, decreased appetite, edema, weight loss, insomnia	[73,74]
5	Ruxolitinib	JAKAFI Incyte Corporation, Wilmington, DE, USA	FDA: 16 November 2011 EMA: 23 August 2012		JAK1 19, JAK2 2	Oral	Myelofibrosis, Polycythemia Vera, Graft-versus-host disease	Anemia, thrombocytopenia, neutropenia	[75,76]

¹ Wrong chemical structure of the drug is given in the reference. ² JAK2: Janus kinase 2. ³ FLT3: FMS-like tyrosine kinase-3. ⁴ AXL: AXL receptor tyrosine kinase. ⁵ ALK: anaplastic lymphoma kinase. ⁶ c-Kit: mast/stem cell growth factor receptor. ⁷ PDGFRA: platelet-derived growth factor receptor α. ⁸ PDGFRB: platelet-derived growth factor receptor β. ⁹ PKC: protein kinase C. ¹⁰ CDK1: cyclin-dependent kinase 1. ¹¹ SYK: spleen tyrosine kinase. ¹² VEGFR-2: vascular endothelial growth factor receptor-2. ¹³ BCR-ABL: BCR-ABL fusion protein. ¹⁴ VEGFRs: vascular endothelial growth factor receptors. ¹⁵ FGFRs: fibroblast growth factor receptors. ¹⁶ PDGFRs: platelet-derived growth factor receptors. ¹⁷ RET: receptor tyrosine kinase rearranged during transfection. ¹⁸ TIE2: tunica interna endothelial cell kinase 2. ¹⁹ JAK1: Janus kinase 1.